Oncolytics Biotech's Reolysin provides 'incredible shrinking returns'

Phase II trial results show strong response to therapy among patients, and the company's stock surges

Jeffrey Bouley
CALGARY—Sometimes, putting a stop to growth is good for a business and incredible shrinking returns are something to look forward to, as evidenced by Oncolytics Biotech Inc.'s Monday announcement that 92 percent of patients in a recent trial experienced tumor shrinkage, a bit of news that caused the company's stock price to surge in Monday trading.
 
Trading opened at $2.93 per share compared to the $2.65 to $2.70 it had been holding at since Sept. 3. It hit a high of about $3.50 near midday, finally settling at $2.99 by the close of day Monday.
 
The company had announced final tumor response data fromits U.S.-based Phase II single-arm clinical trial in patients with squamouscell carcinoma of the lung using intravenous administration ofthe drug Reolysin in combination with carboplatin and paclitaxel (REO 021).
 
The analysis examined "percent best overall tumor responses" betweenpretreatment and up to six treatment cycles. Of 25 evaluable patientswho had more than one cycle of therapy, 23 (roughly 92%) exhibited overalltumor shrinkage at a mean amount of 32.7 percent reduction.
 
"We are thrilled to have demonstrated 92-percent overall tumor shrinkage inthis group of patients," said Dr. Brad Thompson, president and CEO ofOncolytics. "Squamous cell carcinoma of the lung is notoriouslydifficult to treat, and these results support further investigation ofReolysin in randomized clinical trials for this indication."
 
The study enrolled patients with metastatic stage IIIB or stage IV, orrecurrent, squamous cell carcinoma of the lung, who werechemotherapy-naïve for their metastatic or recurrent cancer. Theprimary objective of the trial is to evaluate the patients' tumorresponse. The secondary objectives are to assess progression-freesurvival and overall survival for the treatment regimen in the studypopulation; to determine the proportion of patients receiving the abovetreatment who were alive and free of disease progression at six months;and to assess the safety and tolerability of the treatment regimen inthe study population.
 
Final progression-free survival and safety datafor the study will be reported later in 2013.
 
The American Cancer Society estimates that in 2013, approximately228,190 new cases of lung cancer will be diagnosed. Between 85 percent and 90 percentof all lung cancers are classified as non-small cell lung cancer; squamous cell carcinomas account for 25 percent to 30 percent of all lungcancers. Lung cancer is by far the leading cause of cancer death amongboth men and women, with an expected 159,480 deaths from lungcancer in the United States in 2013, accounting for some 27 percent of allcancer deaths.
 
Oncolytics is a Calgary-based biotechnology company focused on thedevelopment of oncolytic viruses as potential cancer therapeutics.Oncolytics' clinical program includes a variety of human trialsincluding a Phase III trial in head and neck cancers using Reolysin, its proprietary formulation of the human reovirus.
 


Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue